The ALL Channel

Explore the latest updates, including expert interviews, features, podcasts and e-learning
Latest Videos Conferences Topics VJSocial Podcasts Features VJAcademy Editorial Board

Welcome to The Acute Lymphoblastic Leukemia (ALL) Channel

Alongside a world-leading Editorial Board, VJHemOnc can provide all of the latest updates you need in ALL. Speaking directly with the experts at international congresses, The ALL Channel brings you video interviews, podcasts, roundtable discussions and more.

As well as therapy updates including CAR-T, antibody-drug conjugates and chemotherapy, The ALL Channel covers advances in transplantation, measurable residual disease (MRD), managing therapy toxicities, diagnosing ALL and more.

Conferences

EBMT 2023
Tandem Meetings 2023
CAR-T Meeting 2023
ASH 2022
SOHO 2022
EHA 2022
1:56
The feasibility of chemotherapy-free regimens without allogeneic transplantation in MRD- Ph+ALL
David Marks • 24 Apr 2023
3:36
UKALL14: rituximab dose & reduced intensity transplant in B-ALL & nelarabine consolidation in T-ALL
David Marks • 24 Apr 2023
1:37
The importance of MRD assessment before alloSCT in ALL
David Marks • 24 Apr 2023
3:10
GoCART ongoing projects: impact of prior therapy & alloSCT consolidation on CAR-T outcomes in ALL
Valentín Ortiz-Maldonado • 25 May 2023
View All Videos
3:01
Factors driving the use of consolidative SCT following tisa-cel in CAYA with R/R B-ALL
Kevin McNerney • 24 Feb 2023
3:45
LBA: outcomes of children and young adults with B-ALL following tisa-cel reinfusion
Kevin McNerney • 24 Feb 2023
3:11
Predictive factors for HLH toxicity in patients with B-ALL treated with tisa-cel
Kevin McNerney • 24 Feb 2023
4:13
ALL highlights: tisa-cel reinfusion in B-ALL & targeting CD5 and CD7 with CAR-Ts in T-ALL
John DiPersio • 21 Feb 2023
View All Videos
2:11
Exploring strategies to mitigate T-cell exhaustion: treatment-free intervals & small molecules
Marion Subklewe • 10 Feb 2023
1:25
Factors to consider when selecting patients with ALL for transplantation
Arnon Nagler • 10 Feb 2023
4:56
First reported case of CAR-VOD & the role of the endothelium in CAR-related adverse events
Manuela Spadea • 10 Feb 2023
2:37
Insights into the clinical management of CAR-related toxicities
Arnon Nagler • 10 Feb 2023
View All Videos
2:16
Evaluating the safety and efficacy of novel anti-CD7 universal CAR-T therapy in R/R T-ALL and T-LBL
Peihua Lu • 12 Dec 2022
1:11
Exciting updates in ALL and the value of novel immunotherapies
Sara Ghorashian • 11 Dec 2022
3:18
Evaluating dual-targeting CD19/22 CAR-T cells in patients with R/R ALL
Sara Ghorashian • 11 Dec 2022
1:25
The impact of age on the prognosis of patients with ALL
Sabina Chiaretti • 11 Dec 2022
View All Videos
1:09
Using MRD and mutational analysis when selecting patients with T-ALL for transplantation
Josep-Maria Ribera • 3 Oct 2022
1:00
The adverse prognostic impact of complex karyotype in adult T-ALL
Josep-Maria Ribera • 3 Oct 2022
5:16
Approaches to and the use of MRD in ALL
Selina Luger • 6 Oct 2022
1:51
The future of ALL treatment: moving away from stem cell transplantation
Nicholas Short • 29 Oct 2022
View All Videos
5:14
Novel synthetic TCR and antigen receptor (STAR) T-cell therapy for B-ALL
Peihua Lu • 16 Jun 2022
2:34
Exploring chemotherapy-free induction treatment for patients with Ph+ ALL
Robin Foà • 11 Jun 2022
1:20
Managing relapse after CAR-T therapy in ALL
Sara Ghorashian • 12 Jun 2022
5:39
Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL
Peihua Lu • 16 Jun 2022
View All Videos

Topics

Transplant
CAR-T & Cellular Therapy
MRD
Immuno-Oncology
Trial Updates
Treatment
1:56
The feasibility of chemotherapy-free regimens without allogeneic transplantation in MRD- Ph+ALL
David Marks • 24 Apr 2023
3:36
UKALL14: rituximab dose & reduced intensity transplant in B-ALL & nelarabine consolidation in T-ALL
David Marks • 24 Apr 2023
1:37
The importance of MRD assessment before alloSCT in ALL
David Marks • 24 Apr 2023
3:10
GoCART ongoing projects: impact of prior therapy & alloSCT consolidation on CAR-T outcomes in ALL
Valentín Ortiz-Maldonado • 25 May 2023
View All Videos
3:36
UKALL14: rituximab dose & reduced intensity transplant in B-ALL & nelarabine consolidation in T-ALL
David Marks • 24 Apr 2023
3:10
GoCART ongoing projects: impact of prior therapy & alloSCT consolidation on CAR-T outcomes in ALL
Valentín Ortiz-Maldonado • 25 May 2023
3:24
Improving risk stratification in ALL with risk scores & genomic studies to personalize therapy
David Marks • 24 May 2023
1:33
The impact of novel targeted & immune therapies in leukemia
Norbert-Claude Gorin • 23 Apr 2023
View All Videos
1:56
The feasibility of chemotherapy-free regimens without allogeneic transplantation in MRD- Ph+ALL
David Marks • 24 Apr 2023
3:36
UKALL14: rituximab dose & reduced intensity transplant in B-ALL & nelarabine consolidation in T-ALL
David Marks • 24 Apr 2023
1:37
The importance of MRD assessment before alloSCT in ALL
David Marks • 24 Apr 2023
3:24
Improving risk stratification in ALL with risk scores & genomic studies to personalize therapy
David Marks • 24 May 2023
View All Videos
1:56
The feasibility of chemotherapy-free regimens without allogeneic transplantation in MRD- Ph+ALL
David Marks • 24 Apr 2023
3:36
UKALL14: rituximab dose & reduced intensity transplant in B-ALL & nelarabine consolidation in T-ALL
David Marks • 24 Apr 2023
1:37
The importance of MRD assessment before alloSCT in ALL
David Marks • 24 Apr 2023
3:10
GoCART ongoing projects: impact of prior therapy & alloSCT consolidation on CAR-T outcomes in ALL
Valentín Ortiz-Maldonado • 25 May 2023
View All Videos
1:56
The feasibility of chemotherapy-free regimens without allogeneic transplantation in MRD- Ph+ALL
David Marks • 24 Apr 2023
3:36
UKALL14: rituximab dose & reduced intensity transplant in B-ALL & nelarabine consolidation in T-ALL
David Marks • 24 Apr 2023
4:13
Real-world outcomes of patients with R/R B-ALL treated with blinatumomab and inotuzumab ozogamicin
Ankita Sen • 25 Apr 2023
3:05
FORUM results: TBI vs myeloablative chemo-based conditioning pre-alloSCT in high-risk pediatric ALL
Christina Peters • 23 Apr 2023
View All Videos
1:56
The feasibility of chemotherapy-free regimens without allogeneic transplantation in MRD- Ph+ALL
David Marks • 24 Apr 2023
3:36
UKALL14: rituximab dose & reduced intensity transplant in B-ALL & nelarabine consolidation in T-ALL
David Marks • 24 Apr 2023
1:37
The importance of MRD assessment before alloSCT in ALL
David Marks • 24 Apr 2023
3:10
GoCART ongoing projects: impact of prior therapy & alloSCT consolidation on CAR-T outcomes in ALL
Valentín Ortiz-Maldonado • 25 May 2023
View All Videos

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals